Free Newsletter
FDA slaps restrictions on painkillers
Some doctors might call this a pain: FDA is considering new controls on narcotics in hopes of preventing abuse. The agency would restrict the infamous extended-release opioids like OxyContin; it's one of the most abused prescription drugs. The controls would also apply to fentanyl patches, methadone tablets, and some morphine pills, the New York Times reports.
These products already carry various restrictions on their use. But FDA wants to do more, since hundreds of patients die because they took the drugs inappropriately--either by mistake or deliberately--or were given faulty prescriptions in the first place. Plus, companies that make a few of these drugs have run into trouble for overaggressive marketing; Purdue Pharma execs, for instance, pleaded guilty to charges that the company had misled docs into thinking that OxyContin was less likely to be abused because of its long-acting formula.
"What we're talking about is putting in place a program to try to ensure that physicians prescribing these products are properly trained in their safe use, and that only those physicians are prescribing those products," said Dr. John Jenkins, who directs the FDA's new drug center. "It's a massive program."
- read the New York Times story
Related Articles:
FDA blisters Purdue for 'poor' OxyContin data
Pain drug prescriptions skyrocket
Purdue execs plead guilty to OxyContin fraud
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: